Conditions: ST-Segment Elevation Myocardial Infarction
Keywords: Korea Platelet inhibition Prasugrel Ticagrelor ST-segment elevation myocardial infarction
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 39
Healthy volunteers: no

Brief summary:
To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Detailed description:
Prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Both prasugrel and ticagrelor show more rapid and potent antiplatelet effect compared with clopidogrel. However, previous report comparing the efficacy and safety of prasugrel and ticagrelor in patients with STEMI of East Asian ethnicity is lacking. Therefore, the aim of this study is to compare the antiplatelet efficacy and safety using laboratory platelet function tests and clinical outcomes in patients with STEMI treated with either prasugrel or ticagrelor.

Arms:
arm 1: Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose arm 2: Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose

Interventions: intervention 1: Prasugrel 60 mg intervention 2: Ticagrelor 180 mg
Intervention descriptions: intervention 1: Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose. intervention 2: Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.

Protocol document: